Objective: Investigation of the efficacy of acyclovir combined with intravenous human immunoglobulin in the treatment of varicella complicating late pregnancy and analysis of the impact of this regimen on pregnancy outcomes. Methods: 48 pregnant women with varicellain our hospital from January 2018 to December 2020 were collected and divided into control group(acyclovir, n=24) and observation group(acyclovir+intravenous human immunoglobulin, n=24), univariate and multiple linear regression methods were applied to analyze the outcome of treatment for varicella. Results: The efficacy of the observation group was significantly higher than that of the control group. Univariate analysis showed that there were statistically significant differences between the two groups in terms of time to herpes crusting, heat course and complication rate(P<0.05), while there were no significant differences in age, gestational week of onset and gestational week of delivery. Multiple linear regression analysis showed that the time to herpes crusting was positively correlated with heat course(B=0.648,P<0.05), while negatively correlated with treatment method(B=-1.159,P<0.05). When using heat course as the dependent variable, the results indicated a positive correlation with time to herpes crusting(B=0.304,P<0.05) and a negative correlation with treatment method(B=-1.285,P<0.05). Conclusions: Treatment with acyclovir combined with intravenous human immunoglobulin enhances the antiviral effect, shortens the duration of fever and herpes crusting, and reduces complications and relieves clinical symptoms. Delivery should be delayed as much as possible to prevent chickenpox in newborns while ensuring maternal and infant safety. |
[1] GERSHON A A,GERSHON M D,BREUER J,et al.Advances in the understanding of the pathogenesis and epidemiology of herpes zoster[J].J Clin Virol,2010,48(Suppl 1):S2-S7.
[2] GABUTTI G,BOLOGNESI N,SANDRI F,et al.Varicella zoster virus vaccines:an update[J].Immunotargets Ther,2019,8:15-28.
[3] Practice bulletin No.151:cytomegalovirus,parvovirus B19,varicellazoster,and toxoplasmosis in pregnancy[J].Obstet Gynecol,2015,125(6):1510-1525.
[4] 孔德亮,黎玉华,廖梅婷,等.2019-2020 年肇庆市居民乙肝、麻疹、流行性腮腺炎和水痘免疫水平[J].江苏预防医学,2022,33(1):70-71,75
[5] 王朝元,尹玉莹,魏天河,等.ELISA 法对孕前、孕中妇女及新生儿维普创免疫水平研究[J].中南民族大学学报(自然科学版),2020,39(6):591-595.
[6] 李兰娟,任红.传染病学[M].9版.北京:人民卫生出版社,2018:85-88.
[7] 李金玲,谭帅.阿昔洛韦对水痘的治疗价值研究[J].吉林医学,2021,42(8):1901-1902.
[8] 王谢桐.美国妇产科医师协会“妊娠期水痘-带状疱疹病毒感染的临床实践指南”解读[J].中国实用妇科与产科杂志,2016,32(6):508-510.
[9] 何花,范晶华,张燕玲,等.免疫低下人群感染水痘-带状疱疹病毒 38 例的临床特征[J],昆明医科大学学报,2022,43(8):127-131.
[10] 周洁雯,林菁,马丙南,等.63 例儿童重症水痘临床分析[J].中国现代医生,2022,60(18):57-60.
[11] 顾晓霞,高梦洁,丁波.椎管内分娩镇痛产时发热影响因素和干预对策的文献综述[J].东南大学学报(医学版),2021,40(6):865-868.
[12] 黄甜甜,顾晓霞.延迟脐带结扎对足月经阴道分娩母婴结局影响的研究[J].现代医学,2022,50(1):101-104.
[13] 陈艳,陈超,和沁园,等.妊娠期合并症/并发症对感染性产科出生人群短期影响的研究[J].东南大学学报(医学版),2021,40(1):1-6.
[14] 黄华容,何少玲,周琼,等.新生儿水痘感染与孕妇母体水痘-带状疱疹病毒抗体水平的关系[J].中国现代医药杂志 2022,24(9):48-50.
[15] SAUERBREI A.Diagnosis,antiviral therapy,and prophylaxis of varicella-zoster virus infections[J].Eur J Clin Microbiol Infect Dis,2016,35(5):723-734.
[16] LO PRESTI C,CURTI C,MONTANA M,et al.Chickenpox:an update[J].Med Mal Infec,2019,49(1):1-8.
[17] CASTILLO S A,PHAM A K,DINULOS J G.Cutaneous manifestations of systemic viral diseases in neonates:an update[J].Curr Opin Pediatr,2017,29(2):240-248.
[18] HOLLAND C,SADARANGANI M.Fifteen-minute consultation:prevention and treatment of chickenpox in newborns[J].ADC Educ Prac,2020,105(1):24-30.
[19] Varicella and herpes zoster vaccines:WHO position paper,June 2014-Recommendations[J].Vaccine,2016,34(2):198-199.
[20] 随海田,贾涛,郭昱,等.水痘减毒活疫苗应用进展[J].中国病毒病杂志,2022,12(4):316-320. |